67
Participants
Start Date
March 31, 2021
Primary Completion Date
October 26, 2023
Study Completion Date
October 26, 2023
Benralizumab
"Benralizumab subcutaneously (SC) loading dose followed by repeat dosing of SC benralizumab plus Oral Corticosteroids per SoC tapering.~Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure."
Placebo
Placebo plus Oral Corticosteroids per SoC tapering. Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure.
Research Site, Rome
Research Site, Sofia
Research Site, Westmead
Research Site, Kogarah
Research Site, Parkville
Research Site, Haskovo
Research Site, Hohhot
Research Site, Marseille
Research Site, Madrid
Research Site, Madrid
Research Site, Atlanta
Research Site, Margate
Research Site, Bielefeld
Research Site, Bad Bentheim
Research Site, Florence
Research Site, Thessaloniki
Research Site, Lille
Research Site, Tel Aviv
Research Site, Rouen
Research Site, Centennial
Research Site, Phoenix
Research Site, Scottsdale
Research Site, Catania
Research Site, Beijing
Research Site, Shanghai
Research Site, Guangzhou
Research Site, Ramat Gan
Research Site, Beverly
Research Site, Nice
Research Site, Dresden
Research Site, Leipzig
Research Site, Iruma-Gun
Research Site, Kitakyusyu-shi
Research Site, Kurume-shi
Research Site, Okayama
Research Site, Ōta-ku
Research Site, Sapporo
Research Site, Urayasu-shi
Research Site, Alicante
Lead Sponsor
AstraZeneca
INDUSTRY